Telemedicine and psoriatic arthritis: best practices and considerations for dermatologists and rheumatologists
Telemedicine refers to the exchange of medical information through electronic communication methods with the purpose of improving patient health . Technology, services, and tools used in telemedicine are increasingly becoming a vital part of the healthcare system in the USA, especially with the emergence of COVID-19. Telemedicine allows for more patients to maintain ongoing appointments, facilitates triage and screening to assess the need for in-person visits, supports communication for shared decision-making to monitor disease maintenance and changes in therapy, and can prevent discontinuation of long-term treatments that may lapse without physician oversight, all while ensuring social distancing to avoid the risk of exposure to the virus. Telemedicine can also be applied beyond the context of a pandemic to provide healthcare services within or outside of normal clinic hours, to fill gaps in care that may result from provider shortages, and to decrease travel and cost burdens for office visits, especially in rural areas . Many benefits and challenges should be considered before incorporating telemedicine into routine clinical settings (Table ) [ – ]. There are generally 3 types of telemedicine interactions to ensure continuity of care: clinician-to-clinician, clinician-to-patient, and patient-to-mobile health technologies . Telemedicine between healthcare providers can be used for consultation with specialists and colleagues through video, email, and/or telephone and supported by transfer of imaging data or clinical results for review. The synchronous use of telemedicine between patients and their healthcare providers can be applied to manage care for chronic conditions, to evaluate response to medications, to assess patient-reported outcomes (PROs) and changes, for mental health evaluations, and for routine follow-up care . Telemedicine allows patients to have a more active role in their diagnosis and disease management through the use of mobile health tools. Psoriatic arthritis (PsA) is a heterogeneous and complex disease with musculoskeletal and cutaneous involvement, causing potentially severe joint and skin manifestations . PsA is estimated to affect approximately 30% of patients with psoriasis and 0.25% of the total population in the USA . The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) identified 6 clinical domains of disease activity as part of its treatment schema: peripheral arthritis, enthesitis, dactylitis, psoriasis, psoriatic nail disease, and axial disease . GRAPPA and the Outcome Measures in Rheumatology Working Group have also developed and updated a core domain set that should be assessed in clinical trials to include the perspectives of patients and clinicians, with the addition of pain, patient’s global assessment (PtGA), physical function, fatigue, health-related quality of life (QoL), and systemic inflammation . A delay in diagnosis and inadequate treatment of PsA can result in an increase in significant irreversible joint damage and disease burden [ – ], and the integration of telemedicine has the potential to improve access to rheumatologists and dermatologists to avoid preventable delays. 

A workflow protocol for using different types of telemedicine in appointments between a patient and healthcare provider should consist of 3 general stages for effective teleconsultations: previsit screening, day of and during the appointment, and postappointment . Before the appointment, support staff work with patients to provide necessary education to set up and use the technology required for the appointment. The Office for Civil Rights (OCR) at the Department of Health and Human Services (HHS) updated guidance for the use of audio or video communication technology during the pandemic to allow covered healthcare providers to use any non-public facing remote communication product . Outside the context of a public health emergency, when choosing a vendor for virtual visits, the American Medical Association (AMA) has compiled a list of the following key variables to consider to ensure safe and optimal patient care: (1) easy to access, (2) compliant with Health Insurance Portability and Accountability Act of 1996 (HIPAA) and state rules (e.g., willingness to sign a Business Associate Agreement, State Medical Board regulations), (3) has third-party audits, (4) provides options to manage security breaches, (5) user authentication and authorization, (6) transparency on processes used for collected data, (7) in-platform consent capabilities, and (8) dashboard/workflow assimilation . A previsit screening call can be useful to answer questions from the patient, to identify and take photos of key concerns (e.g., skin lesions, dactylitis, nail dystrophy, swollen/tender joints), to ensure appropriate laboratory/imaging tests were completed and shared with the provider, to review expectations for the appointment, and to complete previsit screening and PRO questionnaires. Before seeing patients virtually, providers and support staff should be up to date on current insurance coverage policies to prevent delays in care, because some plans do not cover all aspects of virtual care—including phone calls. On the day of an appointment, the provider can perform subjective and objective assessments, in combination with asking pointed questions and incorporating clinical tests, to comprehensively evaluate the patient. Objective measures include a provider-led physical examination, during which the clinician visually evaluates affected parts of the body through techniques the patient can self-perform, and through presentation of affected areas of the body that are easily visible. Published frameworks of written and visual guidelines are available that include guidance on how to properly conduct a thorough virtual musculoskeletal physical examination and can be used to assess PsA musculoskeletal involvement; these frameworks include general considerations for telemedicine visits, inspections/observations, patient self-palpations, and range of motion and specific detailed tests to evaluate the shoulder, hip, knee, ankle, and cervical and lumbar spine . Provider-guided physical examinations that focus on the digits and commonly affected entheses can be useful to identify the presence of enthesitis and dactylitis. Furthermore, psoriatic nail and skin disease can be assessed through self-evaluation (e.g., body surface area [BSA] “palm rule”  or Self-Administered Psoriasis Area and Severity Index ) and/or store-and-forward high-quality images. During a video assessment, directed questioning and examination of areas of the body commonly affected by psoriatic skin disease can aid in an accurate assessment of skin lesions and help the patient identify areas affected that are not readily visible. Images can facilitate identification of presumed psoriatic lesions to assist in a definitive diagnosis and help properly visualize typical nail disease (e.g., pitting, onycholysis, onychomycosis). Additionally, modern electronic tools for self-examination that were designed for clinical trials—such as smartphone sensor tools, smartphone apps, wearable health monitors, bodily fluid diagnostic devices, wearable patches, mobile dolorimeters, and at-home self-examination kits [ – ], while not widely available—can be used as research tools and are in development for virtual care to directly relay accurate results to providers and increase the assessment capabilities available during virtual appointments . Subjective assessment of a patient’s overall health is important to gauge complete therapeutic response and can include PRO measures and psychiatric evaluations. Validated PRO tools, such as Psoriatic Arthritis Impact of Disease (PsAID)  or Routine Assessment of Patient Index Data 3 (RAPID-3) , can be administered to patients before or during the virtual appointment through patient gateway portals to measure symptoms from the patient’s perspective. Additionally, screening tools that incorporate subjective and/or objective assessments and assist in the early identification of PsA, such as the Psoriasis Epidemiology Screening Tool , can be used during virtual appointments—particularly for high-level screening of patients with suspected PsA. These assessments are useful for triaging new patients and/or evaluating therapeutic responses and disease progression in patients with established disease. Healthcare providers should also be aware of insurance regulations regarding virtual visits, as some policies may not approve of in-person visits < 7 days after a virtual visit or allow for patient care across state lines. Providers may need to be licensed in the state the patient is receiving care during the telemedicine visit. However, a thorough virtual assessment that incorporates available tools can be useful for triaging patients until they are seen in person. Virtual appointments also enable discussions for shared decision-making between patients and providers about treatment options. If changes in treatment plans are necessary, modifications and/or medication switching can be achieved virtually using online portals that directly communicate with pharmacies. After the virtual appointment, personal health data can be transferred to patients’ electronic medical records through a virtual platform. Postvisit considerations include follow-up appointments to schedule in-person evaluations for new patients and consultations and/or referrals to specialists. While telemedicine can be useful for well-controlled follow-up appointments, provide high-level screening for PsA in new patients, and facilitate changes in treatment plans, it does present challenges for a thorough examination—especially in the evaluation of enthesitis and hidden areas of psoriatic involvement and in confirming a diagnosis of PsA. When a definitive diagnosis is needed, a telemedicine visit may allow triage for patients who need to be seen sooner when an in-person visit is delayed. In-person office visits are particularly helpful for new patients who need a thorough physical examination, imaging, or laboratory tests to ensure a comprehensive evaluation. 

The diagnosis and treatment of PsA can be supported by identifying and assessing 6 disease domains (psoriasis, psoriatic nail disease, dactylitis, enthesitis, peripheral arthritis, and axial disease) characteristic of PsA, which can each be evaluated via telemedicine visits or supported with telemedicine tools (Table ). In most patients, psoriasis precedes joint disease, with a typical delay time of 7–12 years from onset to diagnosis of PsA, and psoriatic lesions can develop on the nails, which often present as pitting [ – ]. Video and/or photographic evaluations can provide essential visual information to fully assess new or changing psoriatic skin rash or plaques and psoriatic nail disease. Patients can be educated to use the validated “palm rule” to determine the BSA affected by skin involvement, or clinicians can estimate BSA by assessing the body areas affected (e.g., upper or lower limbs, trunk); however, clinicians should inquire about areas of the body not visible on video (e.g., scalp, genitals) to help provide an accurate self-assessment of skin severity due to psoriasis . The definitive identification of psoriatic disease may not be possible for all presumed skin lesions, and some cases may necessitate an in-person evaluation for a differential diagnosis of psoriasis involvement. Inflammatory features seen in PsA include dactylitis and enthesitis, which present as uniform swelling of entire digits and inflammation at the entheses, respectively. Dactylitis can be evaluated over a video telehealth visit and may be supported by photos. Patients can be directed to compare the suspected digit with the contralateral digit on the opposite hand or foot and to look for signs and symptoms such as redness, warmth to the touch, tenderness, and swelling . Clinicians should incorporate screening for visible signs of enthesitis (which can be rare), such as redness and swelling at insertion sites, and ask the patient about pain upon squeezing commonly affected entheses in virtual examinations to help assess enthesitis . Peripheral arthritis can result in joint pain among patients with PsA—most commonly affecting the knees, fingers, hips, ankles, and wrists . Peripheral arthritis can be addressed by looking for signs of swelling and tenderness at the commonly affected joints. In a clinician-guided musculoskeletal examination, patients may be instructed to palpate their own joints or to perform functional movements on screen (such as walking, so the clinician can assess their gait to understand mobility, the ability to bear weight, and function level), which can be used to evaluate the degree of peripheral arthritis involvement . Axial involvement associated with PsA can occur in 25–70% of patients, often presenting as back stiffness and pain that improves with movement . A high-level evaluation of back pain and stiffness through a clinician-guided physical examination (e.g., lumbar and cervical spine range of motion tests, sacroiliac joint tests, occiput palpation)  and patient-reported questionnaires that address mechanical vs. inflammatory back pain can be conducted during telehealth screening to assess the management of axial disease in patients with PsA. Additionally, clinicians can remotely schedule imaging appointments for patients if needed to better evaluate axial involvement and can virtually review imaging scans if off-site imaging facilities are used. These clinical characteristics can be challenging to evaluate when patients have concurrent symptoms ; in such instances, clinician training and screening tools can help with PsA diagnosis and management. 

Validated screening tools, such as the Psoriasis Epidemiology Screening Tool , have been developed for routine clinical practice and can be applied for telemedicine triage of new patients alongside a thorough patient history to assist in the early detection and identification of PsA in the absence of a face-to-face visit. It is imperative to collect a comprehensive patient history to apply to screening tools and to incorporate risk factors associated with PsA, such as family history. Patients with a family history of PsA have been reported to be 27 to 48 times more likely to develop PsA than controls [ – ]. Screening tools have strengths and weaknesses but can be used to facilitate the early diagnosis of PsA (Table ) . Although not validated as a screening tool, the mnemonic PSA —which represents P ain (joints), S tiffness/ S ausage digit (> 30 min of stiffness after a period of inactivity and/or presence of dactylitis, “sausage digit”), and A xial (axial spine involvement, back pain associated with stiffness and pain that improves with activity)—was developed to help identify the early characteristic features of PsA, particularly for use by general clinicians as a means to identify patients who should be referred to a rheumatologist . This mnemonic is a straightforward way to enhance awareness of PsA, facilitate rapid screening, and emphasize the core features of the disease; patients with psoriasis who have ≥ 2 of the PSA mnemonic items are more likely to develop PsA. Screening tools, especially those with images, provide direction and instruction to help patients understand clinician inquiries, help prevent missed information, and remind clinicians about the proper questions to ask to distinguish PsA. The increased use of proper diagnostic criteria, training to identify distinguishing characteristics of PsA, and screening tools are necessary to decrease the frequency of undiagnosed PsA. 

Disease burden in patients with PsA that is caused by clinical manifestations of the disease can result in significantly poorer QoL compared with the general population [ – ] and similar QoL impairments as patients who have more severe peripheral joint disease activity or other severe rheumatic diseases . All domains are important for the overall assessment of PsA, and the value of understanding the relationship between joint and skin components and their relative contribution to disease burden is imperative to the evaluation of disease progression and management . A myriad of tools for assessing QoL, functional ability, and disease activity are available for PsA and can be applied during telemedicine visits to gauge a patient’s status and therapeutic response . QoL indices that comprise multiple measures of PsA and other rheumatic diseases include the RAPID-3 and PsAID-12/PsAID-9 questionnaires (Table ) [ , , – ]. RAPID-3 is a validated tool to quickly assess patient-reported physical function, pain, and patient global estimate of status . It is responsive to treatments for PsA and has been correlated with measures of disease activity, such as the Disease Activity in Psoriatic Arthritis, Psoriatic Arthritis Disease Activity Score, Disease Activity Score in 28 joints, and Clinical Disease Activity Index [ , – ]. PsAID-9 and PsAID-12 questionnaires were developed by a European League Against Rheumatism task force to provide tools that could assess the impact of PsA from the perspective of the patient . PsAID-12 is used in routine clinical practice and the PsAID-9, a shortened version of PsAID-12, is used primarily in clinical trials . Each component represents a PsA-specific life-impact domain that can assist healthcare providers in making shared decisions with patients about treatment plans. PsAID-9/PsAID-12 scores ≤ 4 represent the P atient- A cceptable S ymptom S tate (PASS); scores > 4 may necessitate a change in treatment plan . PsAID-12 scores have been shown to be significantly correlated with other measures of PsA disease activity and are responsive to treatment [ , , , , – ]. RAPID-3 and PsAID-12 have shown construct validity and are suitable for use in routine clinical settings for patients with PsA . These PRO tools are practical for the continued assessment of the impact of disease and therapeutic response in the absence of in-person visits and are accessible online for patients and clinicians. Questionnaires that assess functional impairment and disease activity can also be used to gauge disease status, progression, and therapeutic response during previsit screenings and follow-up telehealth visits. The Health Assessment Questionnaire Disability Index has been established as an instrument to measure functional disability resulting from disease progression and/or severity . Questions that address fine and locomotor movements of both the upper and lower extremities are included to encompass a comprehensive set of routine functional activities . The Health Assessment Questionnaire Disability Index has been significantly associated with clinical therapeutic response and radiographic progression in patients [ – ]. Online administration of accessible QoL and functional instruments allows for increased frequency of evaluation of disease impact and can provide the opportunity for rapid review, shared decision-making, and easier identification of the need for treatment changes. 

As telemedicine becomes more commonplace, it is important to emphasize healthcare access and maintain treatment regimens for patients with PsA. The use of telemedicine is not a new practice; it has been used in many countries for years to close the gap in access to specialty care in remote and rural areas, with both reported accuracy and satisfaction among patients and clinicians . Reports of patient satisfaction and the accuracy of video consultations support the potential for telemedicine to assist in the high-level screening of patients with suspected PsA and to maintain routine appointments for patients with established disease. Key concerns raised by clinicians about the application of telemedicine include issues related to implementation (particularly for individual practices), payment for services provided, and liability . Several resources from professional organizations and government offices have been created to help providers and support staff navigate the changes required for telemedicine initiation and the challenges that may arise (Table ). The American College of Rheumatology supports the use of telemedicine for appropriate patients, particularly during the COVID-19 pandemic, and defers to rheumatologists and rheumatology healthcare professionals to determine what defines routine, urgent, and emergent care for patients . The AMA and the American Telemedicine Association (ATA) have developed an implementation playbook and a quick-start guide to telehealth, respectively, to provide a comprehensive introduction regarding telemedicine and practical tools to apply for its implementation into clinical practice . The AMA endorses the use of telemedicine and remote care services to ensure the safe management of continued care during the COVID-19 pandemic and for patients in remote areas outside the pandemic setting. The AMA and ATA provide recommendations and guidelines to efficiently set up telemedicine in clinical practice and include resources for healthcare providers to stay current and knowledgeable about telemedicine . Protocols that define when a telemedicine visit is appropriate and how to best conduct a virtual appointment should be developed before implementing telemedicine in a medical practice. Patient education and engagement are important to ensure the success of telemedicine visits, and the AMA and ATA recommend proactive patient outreach and the development of a plan to best support patients on how to access and use telemedicine technology. The associations also outline tips to identify the appropriate platform for optimal care, discuss financial considerations, and provide training guides for support staff. The rules, regulations, and financial aspects of telemedicine are evolving with the increased use of telemedicine services, so it is essential to be aware of the most current information that may impact clinical practices or organizations. Several resources providing rules and regulations on telemedicine policies and guidelines concerning medical coding, reimbursement, and other relevant issues are available, which may vary by state (Table ). During the pandemic, some states temporarily waived licensure requirements to expand interstate access to healthcare, allowing patients to see out-of-state providers virtually . Recently, all 50 states in the USA and the District of Columbia allowed for the reimbursement of some live video telemedicine services; however, the reimbursement policies vary among states . Coverage policies also vary by state and insurer type; however, both private insurance and Medicaid/Medicare have expanded their coverage to include telemedicine during the pandemic. The Centers for Medicare and Medicaid Services and individual private insurance policies can be used to verify updated telemedicine coverage. The OCR of the HHS relaxed some HIPAA and state-related barriers and the enforcement of some penalties, as long as clinicians act in the best interest of patients. Many of the recent changes in policy concerning the use of telemedicine are tied to the ongoing pandemic and may be temporary; therefore, long-term considerations are needed to establish telemedicine that is sustainable in clinical practice. 

Lessons can be learned from the advances in telemedicine during the pandemic and applied for the development of telemedicine services in rheumatology and dermatology in the future. The ability to deviate from a set office schedule can offer healthcare providers increased autonomy and flexibility concerning patient care, which can potentially diminish provider burnout. Telemedicine also may alleviate extensive provider shortages, which can affect urban and rural communities across many specialties . The projected demand for adult rheumatology providers is estimated to greatly exceed—by up to 102%—the clinical full-time practitioner workforce by 2030, which stresses the need for innovative strategies to manage access to healthcare, such as telemedicine . The introduction of modern technology and tools into routine clinical practice can help advance the use of telemedicine, overcome obstacles to geographic and provider availability, and increase patient engagement in research and disease management . A combination of mobile health devices and telemedicine visits to facilitate communication and data input have been applied in virtual clinical trials with success [ – ] and have been incorporated in planned initiatives to address gaps in PsA research . Substantial reductions in the cost and time to complete clinical trials can be achieved with a shift to virtual methods, which can allow for the centralization of data collection and a decrease in the resources needed to manage participating sites. Technologies available for rheumatologic and/or dermatologic clinical trials include social media outlets for recruitment, online surveys for collection of patient-reported data, virtual study appointments, and online portals for communication between patients and clinical staff . More recently, the incorporation of wearable sensors and handheld exam kits, such as mobile electronic dolorimeters and stethoscopes, into clinical trials and routine clinical practice have increased the options for objective outcome measures that can be easily assessed with accuracy in the absence of a trained clinical provider. Barriers to the application of telemedicine, such as poor internet connectivity, lack of familiarity and discomfort with the use of technology, and limited access to high-quality tools, can be attributed to multiple factors, including patient circumstances and demographics. Limited experience with technology can make it difficult for some patients to access electronic medical record patient portals and to establish optimal conditions to capture quality images and videos. Incorporation of telemedicine into a clinical practice increases the burden to providers and clinical teams, e.g., increased costs associated with training and instruments needed to adapt to virtual care. Additionally, providers will need to stay current on the laws and regulations regarding patient care via telemedicine. Furthermore, patients and providers need to feel confident that these tools meet standards for quality care; otherwise, in-person visits may be preferable. Virtual appointments have some disadvantages: less-personal patient-provider interaction, patient discomfort with being examined virtually, limited ability of the provider to inspect areas of the body via images and/or video, and inability of the provider to conduct certain diagnostic tests. For a complex disease such as PsA, an in-person physical examination may be difficult to replace due to many of these challenges, particularly for new patients who require a definitive diagnosis. A standardized virtual evaluation may be required to ensure a differential PsA diagnosis to prevent treatment delay. Further studies to validate the use of telemedicine tools and instruments, and to increase education and awareness about the capabilities of virtual care, are needed to address these challenges so that telemedicine can be used properly and increasingly incorporated into routine clinical care. The increased incorporation of telemedicine services into clinical practice presents an opportunity for providers to optimize resources and improve patient outcomes. Telemedicine has the potential to increase access to care by rheumatologists and dermatologists, provide opportunities for training and education regarding PsA, save costs, and decrease travel time attributed to office visits. 

PsA is difficult to distinguish from other rheumatic diseases and is commonly misdiagnosed and/or undiagnosed, especially in patients without psoriasis. It is essential that clinicians apply proper screening tools, ask pointed questions to properly evaluate patient symptoms, and use appropriate PRO assessments with telemedicine services. Application of the guidelines and resources described herein has the potential to result in the optimal use of telemedicine in the diagnosis of PsA. 

